Multicenter, postoperative, randomized controlled, open label, phase II clinical trial of recombinant human endostatin on vascular normalization for esophageal squamous cell carcinoma

Trial Profile

Multicenter, postoperative, randomized controlled, open label, phase II clinical trial of recombinant human endostatin on vascular normalization for esophageal squamous cell carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Endostatin (Primary)
  • Indications Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jul 2015 New trial record
    • 02 Jun 2015 Primary endpoint has been met. (overall survival), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top